Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 12/20 | 0.48 |
| ▸ | BCHE | P06276 | 11/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TTPA | P49638 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15820288 | 0.88 | PTGS1 (0.74) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15820289 | 0.88 | PTGS1 (0.74) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15821003 | 0.88 | PTGS1 (0.74) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL17289293 | 0.85 | PTGS1 (0.65) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL1651402 | 0.85 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL1927837 | 0.85 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL8270579 | 0.85 | PTGS1 (0.78) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| (R)-Trolox SCHEMBL615168 | 0.85 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL3226 | 0.85 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL16247633 | 0.85 | PTGS1 (0.78) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181441-A1 | TROLOX-PEPTIDE CONJUGATE AND USE THEREOF | CAREGEN CO., LTD. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230160001-A1 | NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-05-25 | — | — | US | disclosed |
| US-20200308220-A1 | AROMATIC-CATIONIC PEPTIDES CONJUGATED TO ANTIOXIDANTS AND THEIR USE IN TREATING COMPLEX REGIONAL PAIN SYNDROME | CLINICAL RESEARCH INSTITUTE OF MONTREAL (CA) | 2020-10-01 | — | — | US | disclosed |
| WO-2017093897-A1 | AROMATIC-CATIONIC PEPTIDES CONJUGATED TO ANTIOXIDANTS AND THEIR USE IN TREATING COMPLEX REGIONAL PAIN SYNDROME | SCHILLER PETER (CA) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308220-A1 | AROMATIC-CATIONIC PEPTIDES CONJUGATED TO ANTIOXIDANTS AND THEIR USE IN TREATING COMPLEX REGIONAL PAIN SYNDROME | QDPR, TYR, MTPN | PTGS1 2488/4885PTGS2 1677/4885CYP1A2 3422/4885 |
| US-20230181441-A1 | TROLOX-PEPTIDE CONJUGATE AND USE THEREOF | PRDX3, TXNRD3, TXNRD2 | PTGS1 754/4885PTGS2 1253/4885CYP1A2 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.